女性ヘルスケア市場の2030年までの予測：薬剤別、流通チャネル別、用途別、地域別の世界分析

Stratistics MRCによると、世界の女性ヘルスケア市場は2023年に175億米ドルを占め、予測期間中のCAGRは16.2%で、2030年には501億米ドルに達する見込みです。

女性ヘルスケア市場とは、あらゆる年齢層の女性特有の医療ニーズや懸念に対応することを特に対象とした医療サービス、製品、技術のセグメントを指します。これには、リプロダクティブヘルス、妊産婦ケア、婦人科疾患、乳房の健康、更年期管理、様々な性別特有の症状など、幅広い医療セグメントが含まれます。さらに、乳がん、子宮頸がん、骨粗しょう症など、女性が主に罹患する疾患の診断ツール、スクリーニング検査、治療も含まれます。

全米骨粗鬆症財団によると、世界中で骨粗鬆症は50歳以上の800万人以上の女性に影響を及ぼしています。WHOによると、2016年、アジア、アフリカ、南米などの発展途上国では、15～19歳の思春期の女子の妊娠が約2,100万件あった。

女性人口の増加

世界人口のかなりの部分を占める女性の医療ニーズは多様かつ複雑で、思春期から更年期、そしてそれ以降に至るまで、さまざまなライフステージにまたがっています。この人口動向は、女性特有の生理的・医療的要件に対応するよう調整された女性向け医療サービスや製品への注目と投資を促しています。さらに、予防医療に対する意識の高まり、医療技術の進歩、女性の健康促進を目的とした取り組みが、市場の拡大をさらに後押ししています。

経済的制約

多くの女性は経済的な課題に直面しており、定期検診、スクリーニング、投薬、専門治療などの医療を受ける余裕がないです。十分な経済的資源がなければ、女性はケアを受けるのを遅らせたり、完全に見送ったりする可能性があり、健康状態の悪化や医療格差の拡大につながります。しかし、健康保険料や自己負担額は、特に低所得者や包括的な保険に加入していない人にとっては、高額になることがあります。

女性のエンパワーメントとアドボカシー

男女平等に対する意識が高まり、重視されるようになるにつれ、女性は自分の健康を管理し、特定のニーズに合わせた医療サービスへのアクセス向上を求めるようになっています。このエンパワーメントは、女性の健康問題に焦点を当てた研究開発の急増につながり、革新的な治療法、診断法、予防法を生み出しています。さらに、アドボカシー活動によって政策立案者が女性の医療を優先するようになり、医療インフラの改善や、女性のリプロダクティブライツ（性と生殖に関する権利）、妊産婦の健康、避妊へのアクセスを支援する政策につながっています。

リプロダクティブライツと家族計画へのアクセス

法的・規制的障壁は、社会的偏見とともに、避妊、中絶、妊産婦ケアなどの包括的なリプロダクティブ・医療サービスへのアクセスを制限する可能性があります。リプロダクティブライツに対する制限は、女性が自分のリプロダクティブヘルスについて十分な情報を得た上で選択する能力を妨げるだけでなく、安全でない中絶や妊産婦死亡率など、健康上の悪影響をもたらす一因にもなっています。さらに、家族計画サービスへのアクセスにおける格差は、社会から疎外されたコミュニティに不釣り合いに影響し、既存の不平等を悪化させる。

COVID-19の影響：

世界中の医療システムがウイルスの管理に集中する一方で、予防検診、出産前ケア、避妊具へのアクセスなど、日常的な女性の健康サービスは混乱に直面しました。封鎖措置や医療施設の過密化により、予約の延期やサービスの利用が減少し、既存の健康格差が悪化しました。しかし、経済不況は女性に不釣り合いな影響を及ぼし、医療サービスを受ける余裕とアクセスを減少させました。遠隔医療へのシフトはケアにある程度の継続性をもたらしたが、デジタルアクセスや技術リテラシーの格差も浮き彫りにし、社会から疎外された人々にさらなる影響を与えました。

予測期間中、アクトネルセグメントが最大となる見込み

アクトネルは、骨密度の低下と骨折のしやすさを特徴とする骨粗鬆症の予防と治療に使用されるため、予測期間中、女性ヘルスケア市場で圧倒的なシェアを占めていました。骨粗鬆症管理に効果的な治療選択肢を提供することで、アクトネルは女性の骨の健康を促進し、骨折のリスクを低減するのに役立ち、それによって女性の全体的な幸福と生活の質を向上させる。このセグメントの存在は、女性の医療ニーズに応えるだけでなく、骨粗鬆症と骨の健康の重要性に関する認識を高めることにも貢献し、その結果、女性が健康のために積極的な対策を講じる力を与えています。

予測期間中、子宮内膜症セグメントのCAGRが最も高くなると予測される

子宮内膜症セグメントは、予測期間中に有利な成長を示すと予測されます。子宮内膜症は、子宮の内膜に似た組織が子宮の外で増殖する疾患で、世界中で数100万人の女性が罹患し、慢性的な痛みや不妊の問題を引き起こしています。子宮内膜症に対する認識と理解が高まったことで、画像診断技術やバイオマーカーアッセイなどの高度な診断ツールの開発への投資が増加し、早期発見と個別化治療戦略が可能になりました。さらに、製薬会社は子宮内膜症の根本的なメカニズムを標的とした新規薬剤の開発に積極的に取り組んでおり、患者により効果的な症状管理を提供し、生活の質を向上させる可能性があります。

最もシェアの高い地域：

予防医療と健康に対する意識の高まりと重視により、女性の健康サービスや製品に対する需要が高まっており、北米地域が予後期間を通じて市場で最大のシェアを占めています。特に婦人科、産科、生殖医療などのセグメントにおける医療技術の進歩は、治療の選択肢を広げ、治療結果を改善し、市場の地域的成長をさらに促進しています。さらに、強力な医療インフラや保険適用と相まって、政府の支援策が地域全体の女性にとって医療をより身近なものにしています。

CAGRが最も高い地域：

個別化医療は、遺伝子検査、バイオマーカー分析、データ分析などの先端技術を活用し、患者固有の遺伝的体質、ライフスタイル、環境要因に基づいて医療戦略をカスタマイズするものであるため、アジア太平洋は予測期間中に大幅な成長を遂げると推定されます。女性ヘルスケアでは、このアプローチにより、乳がん、生殖機能障害、ホルモンバランスの乱れなどの症状に対して、より正確な診断と的を絞った治療が可能になります。さらに、治療効果を最適化し副作用を最小限に抑えることで、個別化医療は患者の転帰を改善するだけでなく、全体的な医療の質も向上させ、市場の成長を促進する極めて重要な力となっています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます。

• 企業プロファイル
  • 追加市場参入企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推定・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データ鉱業
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• イントロダクション
• 促進要因
• 抑制要因
• 機会
• 脅威
• 用途分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界の女性ヘルスケア市場：薬剤別

• イントロダクション
• アクトネル
• フォルテオ
• ミレーナ
• ヌバリング
• オルソ・トリサイ・ロー（28）
• プレマリン
• プロリア
• レクラスト/アクラスタ
• その他

第6章 世界の女性ヘルスケア市場：流通チャネル別

• イントロダクション
• 小売薬局
• オンラインプロバイダー
• 病院薬局

第7章 世界の女性ヘルスケア市場：用途別

• イントロダクション
• 閉経
• ホルモン性不妊症
• 閉経後骨粗鬆症
• 子宮内膜症
• 避妊薬
• その他

第8章 世界の女性ヘルスケア市場：地域別

• イントロダクション
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他の欧州
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他のアジア太平洋
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他の南米
• 中東・アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他の中東・アフリカ

第9章 主要発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第10章 企業プロファイル

• Agile Therapeutics Inc
• Allergan
• Apothecus Pharmaceutical
• Bayer AG
• Blairex Laboratories
• Ferring Pharmaceuticals
• Lupin Limited
• Mylan NV
• Novartis AG
• Pfizer Inc

List of Tables

• Table 1 Global Women Healthcare Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
• Table 3 Global Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
• Table 4 Global Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
• Table 5 Global Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
• Table 6 Global Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
• Table 7 Global Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
• Table 8 Global Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
• Table 9 Global Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
• Table 10 Global Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
• Table 11 Global Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 12 Global Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 13 Global Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 14 Global Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
• Table 15 Global Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 16 Global Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
• Table 17 Global Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
• Table 18 Global Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
• Table 19 Global Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
• Table 20 Global Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
• Table 21 Global Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
• Table 22 Global Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 23 North America Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
• Table 24 North America Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
• Table 25 North America Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
• Table 26 North America Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
• Table 27 North America Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
• Table 28 North America Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
• Table 29 North America Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
• Table 30 North America Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
• Table 31 North America Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
• Table 32 North America Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
• Table 33 North America Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 34 North America Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 35 North America Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 36 North America Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
• Table 37 North America Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 38 North America Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
• Table 39 North America Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
• Table 40 North America Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
• Table 41 North America Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
• Table 42 North America Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
• Table 43 North America Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
• Table 44 North America Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 45 Europe Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
• Table 46 Europe Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
• Table 47 Europe Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
• Table 48 Europe Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
• Table 49 Europe Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
• Table 50 Europe Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
• Table 51 Europe Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
• Table 52 Europe Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
• Table 53 Europe Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
• Table 54 Europe Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
• Table 55 Europe Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 56 Europe Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 57 Europe Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 58 Europe Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
• Table 59 Europe Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 60 Europe Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
• Table 61 Europe Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
• Table 62 Europe Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
• Table 63 Europe Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
• Table 64 Europe Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
• Table 65 Europe Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
• Table 66 Europe Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 67 Asia Pacific Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
• Table 68 Asia Pacific Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
• Table 69 Asia Pacific Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
• Table 70 Asia Pacific Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
• Table 71 Asia Pacific Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
• Table 72 Asia Pacific Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
• Table 73 Asia Pacific Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
• Table 74 Asia Pacific Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
• Table 75 Asia Pacific Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
• Table 76 Asia Pacific Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
• Table 77 Asia Pacific Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 78 Asia Pacific Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 79 Asia Pacific Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 80 Asia Pacific Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
• Table 81 Asia Pacific Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 82 Asia Pacific Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
• Table 83 Asia Pacific Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
• Table 84 Asia Pacific Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
• Table 85 Asia Pacific Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
• Table 86 Asia Pacific Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
• Table 87 Asia Pacific Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
• Table 88 Asia Pacific Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 89 South America Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
• Table 90 South America Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
• Table 91 South America Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
• Table 92 South America Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
• Table 93 South America Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
• Table 94 South America Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
• Table 95 South America Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
• Table 96 South America Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
• Table 97 South America Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
• Table 98 South America Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
• Table 99 South America Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 100 South America Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 101 South America Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 102 South America Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
• Table 103 South America Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 104 South America Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
• Table 105 South America Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
• Table 106 South America Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
• Table 107 South America Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
• Table 108 South America Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
• Table 109 South America Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
• Table 110 South America Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)
• Table 111 Middle East & Africa Women Healthcare Market Outlook, By Country (2021-2030) ($MN)
• Table 112 Middle East & Africa Women Healthcare Market Outlook, By Drug (2021-2030) ($MN)
• Table 113 Middle East & Africa Women Healthcare Market Outlook, By Actonel (2021-2030) ($MN)
• Table 114 Middle East & Africa Women Healthcare Market Outlook, By Forteo (2021-2030) ($MN)
• Table 115 Middle East & Africa Women Healthcare Market Outlook, By Mirena (2021-2030) ($MN)
• Table 116 Middle East & Africa Women Healthcare Market Outlook, By Nuvaring (2021-2030) ($MN)
• Table 117 Middle East & Africa Women Healthcare Market Outlook, By Ortho Tri-Cy Lo (28) (2021-2030) ($MN)
• Table 118 Middle East & Africa Women Healthcare Market Outlook, By Premarin (2021-2030) ($MN)
• Table 119 Middle East & Africa Women Healthcare Market Outlook, By Prolia (2021-2030) ($MN)
• Table 120 Middle East & Africa Women Healthcare Market Outlook, By Reclast/Aclasta (2021-2030) ($MN)
• Table 121 Middle East & Africa Women Healthcare Market Outlook, By Other Drugs (2021-2030) ($MN)
• Table 122 Middle East & Africa Women Healthcare Market Outlook, By Distribution Channel (2021-2030) ($MN)
• Table 123 Middle East & Africa Women Healthcare Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
• Table 124 Middle East & Africa Women Healthcare Market Outlook, By Online Providers (2021-2030) ($MN)
• Table 125 Middle East & Africa Women Healthcare Market Outlook, By Hospital Pharmacies (2021-2030) ($MN)
• Table 126 Middle East & Africa Women Healthcare Market Outlook, By Application (2021-2030) ($MN)
• Table 127 Middle East & Africa Women Healthcare Market Outlook, By Menopause (2021-2030) ($MN)
• Table 128 Middle East & Africa Women Healthcare Market Outlook, By Hormonal Infertility (2021-2030) ($MN)
• Table 129 Middle East & Africa Women Healthcare Market Outlook, By Postmenopausal Osteoporosis (2021-2030) ($MN)
• Table 130 Middle East & Africa Women Healthcare Market Outlook, By Endometriosis (2021-2030) ($MN)
• Table 131 Middle East & Africa Women Healthcare Market Outlook, By Contraceptives (2021-2030) ($MN)
• Table 132 Middle East & Africa Women Healthcare Market Outlook, By Other Applications (2021-2030) ($MN)

According to Stratistics MRC, the Global Women Healthcare Market is accounted for $17.5 billion in 2023 and is expected to reach $50.1 billion by 2030 growing at a CAGR of 16.2% during the forecast period. It refers to the sector of healthcare services, products, and technologies specifically targeted towards addressing the unique healthcare needs and concerns of women across all age groups. This encompasses a wide range of medical areas, including reproductive health, maternal care, gynecological issues, breast health, menopause management, and various gender-specific conditions. Additionally, it encompasses diagnostic tools, screening tests, and treatments for conditions such as breast cancer, cervical cancer, osteoporosis, and other diseases that predominantly affect women.

According to the National Osteoporosis Foundation, across the globe, osteoporosis affects more than 8 million women over the age of 50. According to the WHO, in 2016, in developing countries such as Asia, Africa, and South America, there were around 21 million pregnancies among adolescent girls aged 15-19 years.

Market Dynamics:

Driver:

Increasing female population

As women constitute a substantial portion of the global population, their healthcare needs are diverse and complex, spanning across various life stages from adolescence to menopause and beyond. This demographic trend is prompting greater attention and investment in women's healthcare services and products tailored to address their unique physiological and medical requirements. Moreover, rising awareness about preventive care, advancements in medical technology, and initiatives aimed at promoting women's health are further fueling market expansion.

Restraint:

Financial constraints

Many women face economic challenges that limit their ability to afford healthcare, including routine check-ups, screenings, medications, and specialized treatments. Without adequate financial resources, women may delay seeking care or forego it altogether, leading to worsened health outcomes and increased healthcare disparities. However, the cost of health insurance and out-of-pocket expenses can be prohibitive, particularly for low-income individuals and those without comprehensive coverage.

Opportunity:

Women's empowerment and advocacy

With increasing awareness and emphasis on gender equality, women are taking charge of their health and demanding better access to healthcare services tailored to their specific needs. This empowerment has led to a surge in research and development focused on women's health issues, resulting in innovative treatments, diagnostics, and preventive measures. Furthermore, advocacy efforts have influenced policymakers to prioritize women's healthcare, leading to improved healthcare infrastructure and policies supporting women's reproductive rights, maternal health, and access to contraception.

Threat:

Reproductive rights and access to family planning

Legal and regulatory barriers, along with societal stigmas, can limit access to comprehensive reproductive healthcare services such as contraception, abortion, and prenatal care. Restrictions on reproductive rights not only impede women's ability to make informed choices about their reproductive health but also contribute to negative health outcomes, including unsafe abortions and maternal mortality. Additionally, disparities in access to family planning services disproportionately affect marginalized communities, exacerbating existing inequalities.

Covid-19 Impact:

While healthcare systems worldwide focused on managing the virus, routine women's health services faced disruptions, including preventive screenings, prenatal care, and access to contraceptives. Lockdown measures and overwhelmed healthcare facilities led to postponed appointments and decreased utilization of services, exacerbating existing health disparities. However, economic downturns disproportionately affected women, leading to reduced affordability and access to healthcare services. The shift towards telemedicine offered some continuity in care but also highlighted disparities in digital access and technology literacy, further impacting marginalized populations.

The actonel segment is expected to be the largest during the forecast period

As it is utilized for the prevention and treatment of osteoporosis, a condition characterized by reduced bone density and increased susceptibility to fractures, Actonel segment commanded the dominant share in the Women Healthcare market over the projected period. By offering an effective therapeutic option for osteoporosis management, Actonel helps to promote bone health and reduce the risk of fractures in women, thereby enhancing their overall well-being and quality of life. This segment's presence not only meets the medical needs of women but also contributes to raising awareness about osteoporosis and the importance of bone health, thus empowering women to take proactive measures for their health.

The endometriosis segment is expected to have the highest CAGR during the forecast period

Endometriosis segment is estimated to witness lucrative growth during the forecast period. Endometriosis, a disorder where tissue similar to the lining of the uterus grows outside the womb, affects millions of women globally, causing chronic pain and fertility issues. The heightened awareness and understanding of endometriosis have led to increased investments in developing advanced diagnostic tools, such as imaging techniques and biomarker assays, enabling early detection and personalized treatment strategies. Additionally, pharmaceutical companies are actively engaged in the development of novel drugs targeting the underlying mechanisms of endometriosis, offering patients more effective symptom management and potentially improving their quality of life.

Region with largest share:

Owing to the increased awareness and emphasis on preventive care and wellness have led to higher demand for women's health services and products, North America region commanded the largest share of the market over the prognosis period. Advancements in medical technology, particularly in areas such as gynecology, obstetrics, and reproductive health, have expanded treatment options and improved outcomes, further driving regional growth in the market. Moreover, supportive government initiatives, coupled with robust healthcare infrastructure and insurance coverage, have made healthcare more accessible to women across the region.

Region with highest CAGR:

Asia Pacific region is estimated to witness substantial growth during the anticipated period as personalized medicine utilizes advanced technologies such as genetic testing, biomarker analysis and data analytics to customize healthcare strategies based on a patient's unique genetic makeup, lifestyle, and environmental factors. In women's healthcare, this approach enables more accurate diagnoses and targeted therapies for conditions like breast cancer, reproductive health disorders and hormonal imbalances. Furthermore, by optimizing treatment efficacy and minimizing adverse effects, personalized medicine not only improves patient outcomes but also enhances overall healthcare quality, making it a pivotal force driving growth in the market.

Key players in the market

Some of the key players in Women Healthcare market include Agile Therapeutics Inc, Allergan, Apothecus Pharmaceutical, Bayer AG, Blairex Laboratories, Ferring Pharmaceuticals, Lupin Limited, Mylan NV, Novartis AG and Pfizer Inc.

Key Developments:

In February 2024, Novartis to acquire cancer-centric MorphoSys for $2.9 bln. Novartis will offer shareholders 68.00 euros per share in cash and take MorphoSys private after the deal, which is contingent on certain conditions, including a minimum acceptance threshold of 65% of MorphoSys' share capital and regulatory clearances.

In September 2022, Lynparza was given clearance in China as the first line of maintenance therapy with bevacizumab for advanced ovarian cancer with homologous recombination deficit (HRD) positivity.

In January 2022, The women's hospital at Jackson Memorial, AdventHealth Celebration, and HCA Florida Healthcare's Medical Center using the Robotic surgical technology, Homins surgical system by Memic Innovative Surgery for gynecological procedures.

Drugs Covered:

• Actonel
• Forteo
• Mirena
• Nuvaring
• Ortho Tri-Cy Lo (28)
• Premarin
• Prolia
• Reclast/Aclasta
• Other Drugs

Distribution Channels Covered:

• Retail Pharmacies
• Online Providers
• Hospital Pharmacies

Applications Covered:

• Menopause
• Hormonal Infertility
• Postmenopausal Osteoporosis
• Endometriosis
• Contraceptives
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 Emerging Markets
• 3.8 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Women Healthcare Market, By Drug

• 5.1 Introduction
• 5.2 Actonel
• 5.3 Forteo
• 5.4 Mirena
• 5.5 Nuvaring
• 5.6 Ortho Tri-Cy Lo (28)
• 5.7 Premarin
• 5.8 Prolia
• 5.9 Reclast/Aclasta
• 5.10 Other Drugs

6 Global Women Healthcare Market, By Distribution Channel

• 6.1 Introduction
• 6.2 Retail Pharmacies
• 6.3 Online Providers
• 6.4 Hospital Pharmacies

7 Global Women Healthcare Market, By Application

• 7.1 Introduction
• 7.2 Menopause
• 7.3 Hormonal Infertility
• 7.4 Postmenopausal Osteoporosis
• 7.5 Endometriosis
• 7.6 Contraceptives
• 7.7 Other Applications

8 Global Women Healthcare Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Agile Therapeutics Inc
• 10.2 Allergan
• 10.3 Apothecus Pharmaceutical
• 10.4 Bayer AG
• 10.5 Blairex Laboratories
• 10.6 Ferring Pharmaceuticals
• 10.7 Lupin Limited
• 10.8 Mylan NV
• 10.9 Novartis AG
• 10.10 Pfizer Inc